Fenofibrate - A lipid-lowering drug - Reduces voluntary alcohol drinking in rats

被引:26
|
作者
Karahanian, Eduardo [1 ]
Quintanilla, Maria Elena [2 ]
Fernandez, Katia [3 ]
Israel, Yedy [2 ]
机构
[1] Univ Autonoma Chile, Ctr Biomed Res, Santiago 7500566, Chile
[2] Univ Chile, ICBM, Fac Med, Mol & Clin Pharmacol Program, Santiago, Chile
[3] Univ Diego Port, Fac Hlth & Dent, Santiago, Chile
关键词
Fibrates; Fenofibrate; Catalase; Alcoholism; Treatment; Peroxisome proliferator-activated receptor; PROLIFERATOR-ACTIVATED RECEPTOR; ETHANOL-METABOLISM; ALPHA AGONIST; BRAIN ACETALDEHYDE; ZUCKER RATS; FATTY-ACIDS; LIVER; DEHYDROGENASE; CATALASE; OXIDATION;
D O I
10.1016/j.alcohol.2014.08.004
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
The administration of disulfiram raises blood acetaldehyde levels when ethanol is ingested, leading to an aversion to alcohol. This study was aimed at assessing the effect of fenofibrate on voluntary ethanol ingestion in rats. Fenofibrate reduces blood triglyceride levels by increasing fatty acid oxidation by liver peroxisomes, along with an increase in the activity of catalase, which can oxidize ethanol to acetaldehyde. UChB drinker rats were allowed to consume alcohol 10% v/v freely for 60 days, until consumption stabilized at around 7 g ethanol/kg/24 h. About 1-1.2 g ethanol/kg of this intake is consumed in the first 2 h of darkness of the circadian cycle. Fenofibrate subsequently administered (50 mg/kg/day by mouth [p.o.]) for 14 days led to a 60-70% (p < 0.001) reduction of 24-h ethanol consumption. When ethanol intake was determined within the first 2 h of darkness, the reduction was 85-90% (p < 0.001). We determined whether animals chronically allowed access to ethanol and subsequently treated with fenofibrate, would a) increase liver catalase activity, and b) increase blood acetaldehyde levels after a 24-h ethanol deprivation and the subsequent administration of 1 g ethanol/kg. The oral administration of 1 g ethanol/kg produced a rapid increase in blood (arterial) acetaldehyde in fenofibrate-treated animals versus controls also administered 1 g/kg ethanol (70 mu M vs. 7 mu M; p < 0.001). Liver catalase activity following fenofibrate treatment was increased 3-fold (p < 0.01). Other hepatic enzymes responsible for the metabolism of ethanol (alcohol dehydrogenase and aldehyde dehydrogenase) remained unchanged. No liver damage was induced, as measured by serum glutamic-pyruvic transaminase (GPT) activity. The effect of fenofibrate in reducing alcohol intake was fully reversible. Overall, in rats allowed chronic ethanol intake, by mouth (p.o.), fenofibrate administration increased liver catalase activity and reduced voluntary ethanol intake. The administration of 1 g ethanol/kg (p.o.) to these animals increased blood acetaldehyde levels in fenofibrate-treated animals, suggesting the possible basis for the reduction in ethanol intake. (C) 2014 Elsevier Inc. All rights reserved.
引用
收藏
页码:665 / 670
页数:6
相关论文
共 50 条
  • [1] FENOFIBRATE -A LIPID-LOWERING DRUG-INCREASES BLOOD ACETALDEHYDE LEVELS AND REDUCES VOLUNTARY ALCOHOL DRINKING IN RATS
    Karahanian, E.
    Rivera-Meza, M.
    Quintanilla, M. E.
    Israel, Y.
    ALCOHOL AND ALCOHOLISM, 2015, 50
  • [2] Improved synthesis of fenofibrate as lipid-lowering drug
    Man, Lili
    Li, Shuliang
    Yang, Hanyue
    Yan, Xianguang
    Dong, Shubo
    Zhang, Zhenming
    Jingxi Huagong/Fine Chemicals, 2023, 40 (07): : 1505 - 1512
  • [3] Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug
    Lee, Jung-Jin
    Jin, Yong-Ri
    Yu, Ji-Yeon
    Munkhtsetseg, Tudev
    Park, Eun-Seok
    Lim, Yong
    Kim, Tack-Joong
    Pyo, Myoung-Yun
    Hong, Jin Tae
    Yoo, Hwan-Soo
    Kim, Youngsoo
    Yun, Yeo-Pyo
    ATHEROSCLEROSIS, 2009, 206 (02) : 375 - 382
  • [4] Rosuvastatin - A new lipid-lowering drug
    不详
    MEDICAL LETTER ON DRUGS AND THERAPEUTICS, 2003, 45 (1167): : 81 - 83
  • [5] Pitavastatin: a distinctive lipid-lowering drug
    Ose, Leiv
    CLINICAL LIPIDOLOGY, 2010, 5 (03) : 309 - 323
  • [6] New indications for lipid-lowering drug
    不详
    GERIATRICS, 1996, 51 (12) : 24 - 24
  • [7] Lipid-lowering drug therapies: the evidence
    Packard, C
    PROCEEDINGS OF THE NUTRITION SOCIETY, 2000, 59 (03) : 423 - 424
  • [8] LIPID-LOWERING DRUG-THERAPY
    GRETEN, H
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1987, 112 (36) : 1395 - 1395
  • [9] LIPID-LOWERING ACTIVITY OF PHYTOSTANOLS IN RATS
    SUGANO, M
    KAMO, F
    IKEDA, I
    MORIOKA, H
    ATHEROSCLEROSIS, 1976, 24 (1-2) : 301 - 309
  • [10] Fenofibrate, probucol, and other lipid-lowering treatments in heart transplant recipients
    deLorgeril, M
    Boissonnat, P
    Salen, P
    Monjaud, I
    Dureau, G
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 1996, 15 (05): : 539 - 540